AU2008322595B2 - Method of treating arthritis - Google Patents
Method of treating arthritis Download PDFInfo
- Publication number
- AU2008322595B2 AU2008322595B2 AU2008322595A AU2008322595A AU2008322595B2 AU 2008322595 B2 AU2008322595 B2 AU 2008322595B2 AU 2008322595 A AU2008322595 A AU 2008322595A AU 2008322595 A AU2008322595 A AU 2008322595A AU 2008322595 B2 AU2008322595 B2 AU 2008322595B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- amino
- benzoyl
- piperazin
- phenylsulfanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 19
- -1 (trifluoromethyl)sulfonyl Chemical group 0.000 claims description 349
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 315
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 232
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 142
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 130
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 112
- 150000002390 heteroarenes Chemical class 0.000 claims description 102
- 150000001924 cycloalkanes Chemical class 0.000 claims description 76
- 150000001925 cycloalkenes Chemical class 0.000 claims description 75
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 41
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims description 8
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 102220598631 5-hydroxytryptamine receptor 1E_R49A_mutation Human genes 0.000 claims description 4
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims description 4
- 102220595577 Major vault protein_R24A_mutation Human genes 0.000 claims description 4
- 102220608648 Methyl-CpG-binding domain protein 1_R30A_mutation Human genes 0.000 claims description 4
- 102220507264 Rab11 family-interacting protein 1_R29A_mutation Human genes 0.000 claims description 4
- 102220580225 Thioredoxin domain-containing protein 11_R25A_mutation Human genes 0.000 claims description 4
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 3
- 102220473072 Chemerin-like receptor 2_R14Q_mutation Human genes 0.000 claims description 3
- 102220506785 Vitelline membrane outer layer protein 1 homolog_R44A_mutation Human genes 0.000 claims description 3
- 102220598664 5-hydroxytryptamine receptor 1E_R36A_mutation Human genes 0.000 claims description 2
- 102220598618 5-hydroxytryptamine receptor 1E_R43A_mutation Human genes 0.000 claims description 2
- 102220598653 5-hydroxytryptamine receptor 1E_R53A_mutation Human genes 0.000 claims description 2
- 101100294120 Caenorhabditis elegans nhr-55 gene Proteins 0.000 claims description 2
- 102220614548 Calmodulin-3_R23A_mutation Human genes 0.000 claims description 2
- 102220605470 Coilin_R15A_mutation Human genes 0.000 claims description 2
- 102220605399 Coilin_R40A_mutation Human genes 0.000 claims description 2
- 102220503974 Endogenous retrovirus group K member 6 Rec protein_R13A_mutation Human genes 0.000 claims description 2
- 102220503968 Endogenous retrovirus group K member 6 Rec protein_R20A_mutation Human genes 0.000 claims description 2
- 102220642468 Gap junction alpha-8 protein_R19A_mutation Human genes 0.000 claims description 2
- 102220642537 Gap junction alpha-8 protein_R28A_mutation Human genes 0.000 claims description 2
- 102220642541 Gap junction alpha-8 protein_R47A_mutation Human genes 0.000 claims description 2
- 102220595473 Major vault protein_R18A_mutation Human genes 0.000 claims description 2
- 102220595571 Major vault protein_R52A_mutation Human genes 0.000 claims description 2
- 102220507254 Rab11 family-interacting protein 1_R38K_mutation Human genes 0.000 claims description 2
- 102220507253 Rab11 family-interacting protein 1_R42A_mutation Human genes 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims description 2
- 101150009274 nhr-1 gene Proteins 0.000 claims description 2
- 102220264184 rs1554736515 Human genes 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 102220519218 Trypsin-2_R31A_mutation Human genes 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical group [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- 102220507255 Rab11 family-interacting protein 1_R39K_mutation Human genes 0.000 claims 1
- 102220519117 Trypsin-2_R48A_mutation Human genes 0.000 claims 1
- 102220500097 eIF5-mimic protein 2_R34A_mutation Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 170
- 239000004305 biphenyl Substances 0.000 description 83
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 18
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- AFFPZJFLSDVZBV-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C(F)(F)F AFFPZJFLSDVZBV-UHFFFAOYSA-N 0.000 description 8
- HSDKYMBTTJDKGD-UHFFFAOYSA-N 3-(trifluoromethylsulfonyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 HSDKYMBTTJDKGD-UHFFFAOYSA-N 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 235000010290 biphenyl Nutrition 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000312 peanut oil Substances 0.000 description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108700012920 TNF Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- HONQJOPLJZFOJD-UHFFFAOYSA-N 2-[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]-3-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1C(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1 HONQJOPLJZFOJD-UHFFFAOYSA-N 0.000 description 3
- JGFUXOJZXVHGSY-UHFFFAOYSA-N 2-ethylsulfonylbenzenesulfonamide Chemical compound CCS(=O)(=O)C1=CC=CC=C1S(N)(=O)=O JGFUXOJZXVHGSY-UHFFFAOYSA-N 0.000 description 3
- MUMNFEPQABVDQS-UHFFFAOYSA-N 2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)C1=CC=CC=C1S(N)(=O)=O MUMNFEPQABVDQS-UHFFFAOYSA-N 0.000 description 3
- TXTQURPQLVHJRE-UHFFFAOYSA-N 3-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 TXTQURPQLVHJRE-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 102220614557 Calmodulin-3_R31A_mutation Human genes 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- YLSHYCDYLGLAFB-UHFFFAOYSA-N 2-phenylsulfanylbutanamide Chemical compound CCC(C(N)=O)SC1=CC=CC=C1 YLSHYCDYLGLAFB-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- YIRNNHURQFNQDX-UHFFFAOYSA-N 3,6-dihydro-2h-pyridine-1-carboxylic acid Chemical compound OC(=O)N1CCC=CC1 YIRNNHURQFNQDX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- XZOWIJDBQIHMFC-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O.CCCC(N)=O XZOWIJDBQIHMFC-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- PCCPERGCFKIYIS-AWEZNQCLSA-N daxalipram Chemical compound C1=C(OC)C(OCCC)=CC([C@@]2(C)OC(=O)NC2)=C1 PCCPERGCFKIYIS-AWEZNQCLSA-N 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229950007278 lenercept Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229960004110 olsalazine Drugs 0.000 description 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- NITUEMISTORFON-PPFXTMJRSA-N (2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N)C(C)C)C(C)C)C1=CC=CC=C1 NITUEMISTORFON-PPFXTMJRSA-N 0.000 description 1
- SFGFYNXPJMOUHK-PKAFTLKUSA-N (2r)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-n-[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[(2r)-1-[[2-[[(2r)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohe Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)NCC(=O)N[C@@H](C(N)=O)CC1=CC=C(O)C=C1 SFGFYNXPJMOUHK-PKAFTLKUSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BDMMMBUBFVCZFA-WGYIJZORSA-N (2s)-1-[(3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 BDMMMBUBFVCZFA-WGYIJZORSA-N 0.000 description 1
- DRSJLVGDSNWQBI-SFHVURJKSA-N (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(2,6-dimethoxyphenyl)phenyl]propanoic acid Chemical compound COC1=CC=CC(OC)=C1C(C=C1)=CC=C1C[C@@H](C(O)=O)NC(=O)C1=C(Cl)C=CC=C1Cl DRSJLVGDSNWQBI-SFHVURJKSA-N 0.000 description 1
- OTHYPAMNTUGKDK-UHFFFAOYSA-N (3-acetylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(C(C)=O)=C1 OTHYPAMNTUGKDK-UHFFFAOYSA-N 0.000 description 1
- ULTMDKZXHAEJJP-JGCGQSQUSA-N (3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutanoic acid Chemical compound C([C@@H](CC(=O)O)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 ULTMDKZXHAEJJP-JGCGQSQUSA-N 0.000 description 1
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- IRELROQHIPLASX-SEYXRHQNSA-N (z)-2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide Chemical compound C#CCCC(/O)=C(\C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 IRELROQHIPLASX-SEYXRHQNSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- IEMUECOTLKXVOF-PSXMRANNSA-N 1-[(3r)-3-[4-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitroanilino]-4-phenylsulfanylbutyl]azetidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CN1CC[C@@H](NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)CSC1=CC=CC=C1 IEMUECOTLKXVOF-PSXMRANNSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-M 2,2-dimethylbutanoate Chemical compound CCC(C)(C)C([O-])=O VUAXHMVRKOTJKP-UHFFFAOYSA-M 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- HIFGQHGWMTZMOH-UHFFFAOYSA-N 2-(trifluoromethoxy)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1OC(F)(F)F HIFGQHGWMTZMOH-UHFFFAOYSA-N 0.000 description 1
- AMNKRBRQQAMACZ-UHFFFAOYSA-N 2-[(4-ethynyl-2-fluorophenyl)amino]-3,4-difluoro-n-(2-hydroxyethoxy)benzamide Chemical compound OCCONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(C#C)C=C1F AMNKRBRQQAMACZ-UHFFFAOYSA-N 0.000 description 1
- QYJXXSWGFZRQJL-UHFFFAOYSA-N 2-[4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]-3-(trifluoromethylsulfonyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(S(=O)(=O)C(F)(F)F)=C1C(=O)C1=CC=C(N2CCN(CC=3CCCCC=3C=3C=CC(Cl)=CC=3)CC2)C=C1 QYJXXSWGFZRQJL-UHFFFAOYSA-N 0.000 description 1
- CFESRDYSPSLNDJ-UHFFFAOYSA-N 2-[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound ClC1=CC=C(C=C1)C1=C(C=CC=C1)CN1CCN(CC1)C1=CC=C(C(=O)C2=C(C=CC=C2C(F)(F)F)S(=O)(=O)N)C=C1 CFESRDYSPSLNDJ-UHFFFAOYSA-N 0.000 description 1
- RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KUTLGSQTGUZNFX-UHFFFAOYSA-N 3,5-difluoro-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=C(F)C(N3CCN(CC=4C(=CC=CC=4)C=4C=CC=CC=4)CC3)=C(F)C=2)=CC=C1NCCSC1=CC=CC=C1 KUTLGSQTGUZNFX-UHFFFAOYSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- KGDHHYBPYWBFCD-UHFFFAOYSA-N 3-fluoro-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=C(F)C(N3CCN(CC=4C(=CC=CC=4)C=4C=CC=CC=4)CC3)=CC=2)=CC=C1NCCSC1=CC=CC=C1 KGDHHYBPYWBFCD-UHFFFAOYSA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- QLLPPZYXDAFJMH-UHFFFAOYSA-N 4-[4-(2-morpholin-4-ylethoxy)-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCOCC2)=CC=C1NCCSC1=CC=CC=C1 QLLPPZYXDAFJMH-UHFFFAOYSA-N 0.000 description 1
- WQTRCQYEHDMLOS-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NCCSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OCCN(C)C)CC1=CC=CC=C1C1=CC=CC=C1 WQTRCQYEHDMLOS-UHFFFAOYSA-N 0.000 description 1
- RMUNYJUAFSZGPE-UHFFFAOYSA-N 4-[4-[2-(dimethylamino)ethoxy]-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC(C)(C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OCCN(C)C)CC1=CC=CC=C1C1=CC=CC=C1 RMUNYJUAFSZGPE-UHFFFAOYSA-N 0.000 description 1
- AAEKHMJVLMKCMS-UHFFFAOYSA-N 4-[4-[[1-(4-chlorophenyl)naphthalen-2-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=C4C=CC=CC4=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 AAEKHMJVLMKCMS-UHFFFAOYSA-N 0.000 description 1
- YNSIZZJGCAZVNR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-N-(3-nitrophenyl)sulfonylbenzamide Chemical compound ClC1=CC=C(C=C1)C1=C(CCCC1)CN1CCN(CC1)C1=CC=C(C(=O)NS(=O)(=O)C2=CC(=CC=C2)[N+](=O)[O-])C=C1 YNSIZZJGCAZVNR-UHFFFAOYSA-N 0.000 description 1
- JCBWVZTWDSQBJN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3CCCCC=3C=3C=CC(Cl)=CC=3)CC2)=C1 JCBWVZTWDSQBJN-UHFFFAOYSA-N 0.000 description 1
- MCSWNPCWNMROGX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]-4-methoxypiperidin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NCCSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=C(Cl)C=C1 MCSWNPCWNMROGX-UHFFFAOYSA-N 0.000 description 1
- CQEPWMHPRDDCIE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(3-nitrophenyl)sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=C1 CQEPWMHPRDDCIE-UHFFFAOYSA-N 0.000 description 1
- HUHAEUZLTJSJAY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-(2-phenylsulfanylethyl)benzimidazol-5-yl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3N=CN(CCSC=4C=CC=CC=4)C3=CC=2)CC1 HUHAEUZLTJSJAY-UHFFFAOYSA-N 0.000 description 1
- KGPOVMZKWZQOBM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[1-(2-phenylsulfanylethyl)benzotriazol-5-yl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C3N=NN(CCSC=4C=CC=CC=4)C3=CC=2)CC1 KGPOVMZKWZQOBM-UHFFFAOYSA-N 0.000 description 1
- QAPUEVZEKMJEBK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-methylsulfonyl-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound CS(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 QAPUEVZEKMJEBK-UHFFFAOYSA-N 0.000 description 1
- NEPOFLDEWYDKHS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenoxyethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCOC1=CC=CC=C1 NEPOFLDEWYDKHS-UHFFFAOYSA-N 0.000 description 1
- FLYKUMZSSODUOO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethoxy)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1OCCSC1=CC=CC=C1 FLYKUMZSSODUOO-UHFFFAOYSA-N 0.000 description 1
- ADCOBALVMDMDHV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-pyridin-4-ylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=NC=C1 ADCOBALVMDMDHV-UHFFFAOYSA-N 0.000 description 1
- WRVVLOISIOLCEO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[(4-phenylsulfanyloxolan-3-yl)amino]phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NC1COCC1SC1=CC=CC=C1 WRVVLOISIOLCEO-UHFFFAOYSA-N 0.000 description 1
- PGWDIDAHAHZMJO-QJUVWIGKSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[(2r)-4-[(1r,4r)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1-phenylsulfanylbutan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN1C[C@@]2(OC[C@@]1([H])C2)[H])NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 PGWDIDAHAHZMJO-QJUVWIGKSA-N 0.000 description 1
- QDEMJEPWDPZMFX-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[(2r)-4-oxo-1-phenylsulfanyl-4-(propan-2-ylamino)butan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@@H](CC(=O)NC(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 QDEMJEPWDPZMFX-PGUFJCEWSA-N 0.000 description 1
- KJPMVHNZOCEBLW-XIFFEERXSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[(2s)-1-phenylsulfanylbutan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@H](CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 KJPMVHNZOCEBLW-XIFFEERXSA-N 0.000 description 1
- LISKPNGQDQXKGY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[1-(phenylsulfanylmethyl)cyclohexyl]amino]phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NC1(CSC=2C=CC=CC=2)CCCCC1 LISKPNGQDQXKGY-UHFFFAOYSA-N 0.000 description 1
- YQLLHLLCDXLVET-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[1-(phenylsulfanylmethyl)cyclopropyl]amino]phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NC1(CSC=2C=CC=CC=2)CC1 YQLLHLLCDXLVET-UHFFFAOYSA-N 0.000 description 1
- MFJRHOLIZYEXOV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(2-phenylsulfanylethoxy)-3-(trifluoromethyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1OCCSC1=CC=CC=C1 MFJRHOLIZYEXOV-UHFFFAOYSA-N 0.000 description 1
- IZNNGVLJDKUVEC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(1-methyl-4-phenylsulfanylpyrrolidin-3-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=CC=CC=1SC1CN(C)CC1NC(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 IZNNGVLJDKUVEC-UHFFFAOYSA-N 0.000 description 1
- BZXZQPIODBLYAH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-methylsulfonylphenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C(S(C)(=O)=O)C=1NC(C)(C)CSC1=CC=CC=C1 BZXZQPIODBLYAH-UHFFFAOYSA-N 0.000 description 1
- ADJAPRGSLCJMDA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-pyrimidin-2-ylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=NC=CC=N1 ADJAPRGSLCJMDA-UHFFFAOYSA-N 0.000 description 1
- TTXSYIBMYHALFP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-thiophen-2-ylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CS1 TTXSYIBMYHALFP-UHFFFAOYSA-N 0.000 description 1
- YHBYDAFRIMVTTR-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(cyclopropylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CC(=O)NC1CC1)SC1=CC=CC=C1 YHBYDAFRIMVTTR-PGUFJCEWSA-N 0.000 description 1
- AEIUATLKIVAZKM-UUWRZZSWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CC(=O)N(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 AEIUATLKIVAZKM-UUWRZZSWSA-N 0.000 description 1
- VRJBBTYKHSULRH-MGBGTMOVSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(methylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CC(=O)NC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 VRJBBTYKHSULRH-MGBGTMOVSA-N 0.000 description 1
- GGWKAGRGSWXFIW-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[di(propan-2-yl)amino]-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CC(=O)N(C(C)C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GGWKAGRGSWXFIW-KXQOOQHDSA-N 0.000 description 1
- CCNIPYGCOPRPKJ-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-[methyl(propan-2-yl)amino]-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-methylsulfonylphenyl]sulfonylbenzamide Chemical compound C([C@@H](CC(=O)N(C)C(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)S(C)(=O)=O)SC1=CC=CC=C1 CCNIPYGCOPRPKJ-DIPNUNPCSA-N 0.000 description 1
- BHCQEPSHDIRJTJ-DIPNUNPCSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 BHCQEPSHDIRJTJ-DIPNUNPCSA-N 0.000 description 1
- BBXCGKDNLWSQFH-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-6-[[2-(dimethylamino)acetyl]amino]-1-phenylsulfanylhexan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCCCNC(=O)CN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 BBXCGKDNLWSQFH-KXQOOQHDSA-N 0.000 description 1
- HPLNQCPCUACXLM-DHUJRADRSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-DHUJRADRSA-N 0.000 description 1
- GHSKMLGVXKTGGZ-QLKFWGTOSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-(dimethylamino)-2-methyl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@](C)(CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 GHSKMLGVXKTGGZ-QLKFWGTOSA-N 0.000 description 1
- LWHMFWQPHKVIFL-DHUJRADRSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2s)-4-methyl-1-phenylsulfanylpentan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@H](CC(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LWHMFWQPHKVIFL-DHUJRADRSA-N 0.000 description 1
- ZEFVUWLHJINFIV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[2-methyl-1-(1,3-thiazol-2-ylsulfanyl)propan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=NC=CS1 ZEFVUWLHJINFIV-UHFFFAOYSA-N 0.000 description 1
- XTSMCEWYBFSBQJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)pyridin-3-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=NC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 XTSMCEWYBFSBQJ-UHFFFAOYSA-N 0.000 description 1
- QCXCXGFMCKUXBY-UHFFFAOYSA-N 4-[4-[[2-[4-(2-morpholin-4-ylethoxy)phenyl]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(OCCN4CCOCC4)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 QCXCXGFMCKUXBY-UHFFFAOYSA-N 0.000 description 1
- VARCXVHHCSGHDW-UHFFFAOYSA-N 4-[4-[[2-[4-[2-(dimethylamino)ethoxy]phenyl]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonylbenzamide Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NCCSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 VARCXVHHCSGHDW-UHFFFAOYSA-N 0.000 description 1
- OCYXKXWZWZZVQH-UHFFFAOYSA-N 4-[4-[[2-[4-[2-(dimethylamino)ethoxy]phenyl]phenyl]methyl]piperazin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC(C)(C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 OCYXKXWZWZZVQH-UHFFFAOYSA-N 0.000 description 1
- BNLMRSZXGYDZLT-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-3,6-dihydro-2h-pyran-5-yl]methyl]piperazin-1-yl]-n-[3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3COCCC=3C=3C=CC(Cl)=CC=3)CC2)=C1 BNLMRSZXGYDZLT-UHFFFAOYSA-N 0.000 description 1
- MQSGFLQJEGSELO-UMSFTDKQSA-N 4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[3-nitro-4-[[(2s)-1-phenylsulfanylbutan-2-yl]amino]phenyl]sulfonylbenzamide Chemical compound C([C@H](CC)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCC(CC=2C(=CC=CC=2)C=2C=CC=CC=2)(CC1)OC)[N+]([O-])=O)SC1=CC=CC=C1 MQSGFLQJEGSELO-UMSFTDKQSA-N 0.000 description 1
- QNDKCECSDURSNV-UHFFFAOYSA-N 4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[3-nitro-4-[[1-(phenylsulfanylmethyl)cyclopentyl]amino]phenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC3(CSC=4C=CC=CC=4)CCCC3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 QNDKCECSDURSNV-UHFFFAOYSA-N 0.000 description 1
- RESXXHNUHBEYDA-UHFFFAOYSA-N 4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC(C)(C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 RESXXHNUHBEYDA-UHFFFAOYSA-N 0.000 description 1
- FBPNGFUNOCHSQN-BHVANESWSA-N 4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]-n-[4-[[(2s)-4-methyl-1-phenylsulfanylpentan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CSC=3C=CC=CC=3)CC(C)C)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 FBPNGFUNOCHSQN-BHVANESWSA-N 0.000 description 1
- GVJKLSTZIFMTKH-CQSZACIVSA-N 4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzenesulfonamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(N)(=O)=O)[N+]([O-])=O)SC1=CC=CC=C1 GVJKLSTZIFMTKH-CQSZACIVSA-N 0.000 description 1
- DJKNRCWSXSZACF-UHFFFAOYSA-N 4-acetamido-n-tert-butylbenzamide Chemical compound CC(=O)NC1=CC=C(C(=O)NC(C)(C)C)C=C1 DJKNRCWSXSZACF-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- AZNQLJPNUVWYKV-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(N)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 AZNQLJPNUVWYKV-UUWRZZSWSA-N 0.000 description 1
- PBPXJHCPGGJPGA-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzoic acid Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(O)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 PBPXJHCPGGJPGA-UUWRZZSWSA-N 0.000 description 1
- PQPAZFYAWSKVQT-UUWRZZSWSA-N 5-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzoic acid Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1C(O)=O)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 PQPAZFYAWSKVQT-UUWRZZSWSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- SVAGFBGXEWPNJC-SPIKMXEPSA-N 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN SVAGFBGXEWPNJC-SPIKMXEPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- NGIYTUGOGMSBPP-UHFFFAOYSA-N C1(CCCCC1)N(C)C1=C(C=CC=C1[N+](=O)[O-])S(=O)(=O)N Chemical compound C1(CCCCC1)N(C)C1=C(C=CC=C1[N+](=O)[O-])S(=O)(=O)N NGIYTUGOGMSBPP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QQJRZZSEDSEJGJ-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=C(CCCCC1)CN1CCN(CC1)C1=CC=C(C(=O)NS(=O)(=O)C2=CC(=CC=C2)S(=O)(=O)C(F)(F)F)C=C1 Chemical compound ClC1=CC=C(C=C1)C1=C(CCCCC1)CN1CCN(CC1)C1=CC=C(C(=O)NS(=O)(=O)C2=CC(=CC=C2)S(=O)(=O)C(F)(F)F)C=C1 QQJRZZSEDSEJGJ-UHFFFAOYSA-N 0.000 description 1
- WWODFRUWRABRNY-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=C(COCC1)CN1CCN(CC1)C1=CC=C(C(=O)C2=C(C=CC=C2S(=O)(=O)C(F)(F)F)S(=O)(=O)N)C=C1 Chemical compound ClC1=CC=C(C=C1)C1=C(COCC1)CN1CCN(CC1)C1=CC=C(C(=O)C2=C(C=CC=C2S(=O)(=O)C(F)(F)F)S(=O)(=O)N)C=C1 WWODFRUWRABRNY-UHFFFAOYSA-N 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102400000792 Endothelial monocyte-activating polypeptide 2 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 102220608818 Huntingtin-associated protein 1_R34A_mutation Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 229940124137 Interferon gamma antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010016230 MBP-8298 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010005366 RDP 1258 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102220470626 Sterile alpha motif domain-containing protein 1_R48A_mutation Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 229960001683 abetimus Drugs 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108010004614 allotrap Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960000674 colesevelam hydrochloride Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- ROASJEHPZNKHOF-UHFFFAOYSA-N hexyl carbamate Chemical compound CCCCCCOC(N)=O ROASJEHPZNKHOF-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001550 hyoscyamine sulfate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- XODDGHYMROCDOB-PGUFJCEWSA-N methyl 5-[[4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethyl)benzoate Chemical compound C([C@@H](CCN(C)C)NC1=C(C=C(C=C1C(=O)OC)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2CCCCC=2C=2C=CC(Cl)=CC=2)CC1)C(F)(F)F)SC1=CC=CC=C1 XODDGHYMROCDOB-PGUFJCEWSA-N 0.000 description 1
- XKBVBGDNZNPWMV-PGUFJCEWSA-N methyl 5-[[4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrobenzoate Chemical compound C([C@@H](CCN(C)C)NC1=C(C=C(C=C1C(=O)OC)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 XKBVBGDNZNPWMV-PGUFJCEWSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 229960002853 midazolam hydrochloride Drugs 0.000 description 1
- PLYSCVSCYOQVRP-UHFFFAOYSA-N midazolam hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F PLYSCVSCYOQVRP-UHFFFAOYSA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- PXJBGEBRSFGPHB-UHFFFAOYSA-N n-(4-cyclohexyloxy-3-nitrophenyl)sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1OC1CCCCC1 PXJBGEBRSFGPHB-UHFFFAOYSA-N 0.000 description 1
- GISSVSCXLUOIEX-UHFFFAOYSA-N n-[3-amino-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound NC1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 GISSVSCXLUOIEX-UHFFFAOYSA-N 0.000 description 1
- GWEZVJSUXZHAQI-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(1-phenylimidazol-2-yl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3N(C=CN=3)C=3C=CC=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 GWEZVJSUXZHAQI-UHFFFAOYSA-N 0.000 description 1
- KATQATSQFAUAPZ-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-piperidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCCC2)=CC=C1NCCSC1=CC=CC=C1 KATQATSQFAUAPZ-UHFFFAOYSA-N 0.000 description 1
- CGNQZNPEHXRXJZ-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-pyrrolidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCC2)=CC=C1NCCSC1=CC=CC=C1 CGNQZNPEHXRXJZ-UHFFFAOYSA-N 0.000 description 1
- JFGZNMKXLLMALJ-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 JFGZNMKXLLMALJ-UHFFFAOYSA-N 0.000 description 1
- BFUOPEFJSRJKCY-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylpyrazol-3-yl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3N(N=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 BFUOPEFJSRJKCY-UHFFFAOYSA-N 0.000 description 1
- KVPUIXQJKRNNSW-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(2-phenylpyridin-3-yl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=NC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 KVPUIXQJKRNNSW-UHFFFAOYSA-N 0.000 description 1
- YLCRSPIQOMEPHX-UHFFFAOYSA-N n-[3-nitro-4-(2-phenylsulfanylethylamino)phenyl]sulfonyl-4-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C=C(C=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 YLCRSPIQOMEPHX-UHFFFAOYSA-N 0.000 description 1
- SVYOCXMCZXVUPF-UHFFFAOYSA-N n-[3-nitro-4-[(4-phenylsulfanyloxolan-3-yl)amino]phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NC1COCC1SC1=CC=CC=C1 SVYOCXMCZXVUPF-UHFFFAOYSA-N 0.000 description 1
- LABLRYLZYWMPDY-LJAQVGFWSA-N n-[3-nitro-4-[[(2s)-1-phenylsulfanylpropan-2-yl]amino]phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@H](C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 LABLRYLZYWMPDY-LJAQVGFWSA-N 0.000 description 1
- KYTVBQQEZPLFOP-UHFFFAOYSA-N n-[3-nitro-4-[[1-(phenylsulfanylmethyl)cyclopentyl]amino]phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-piperidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCCC2)=CC=C1NC1(CSC=2C=CC=CC=2)CCCC1 KYTVBQQEZPLFOP-UHFFFAOYSA-N 0.000 description 1
- HCCAHFFRPQCQNZ-UHFFFAOYSA-N n-[3-nitro-4-[[1-(phenylsulfanylmethyl)cyclopentyl]amino]phenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NC1(CSC=2C=CC=CC=2)CCCC1 HCCAHFFRPQCQNZ-UHFFFAOYSA-N 0.000 description 1
- MRMMYYPITOQGAT-UHFFFAOYSA-N n-[4-(1-methylpiperidin-4-yl)oxy-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C1[N+]([O-])=O MRMMYYPITOQGAT-UHFFFAOYSA-N 0.000 description 1
- FYQNTAPYEZOSCS-UHFFFAOYSA-N n-[4-(2-cyclohexylethylamino)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCCC1CCCCC1 FYQNTAPYEZOSCS-UHFFFAOYSA-N 0.000 description 1
- ZZFJNKSWNGPSTJ-UHFFFAOYSA-N n-[4-(4,4-dimethylpiperidin-1-yl)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C1CC(C)(C)CCN1C1=CC=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C1[N+]([O-])=O ZZFJNKSWNGPSTJ-UHFFFAOYSA-N 0.000 description 1
- FESBUAOKUZDLTH-UHFFFAOYSA-N n-[4-(cyclohexylamino)-3-nitrophenyl]sulfonyl-4-[4-methoxy-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(NC3CCCCC3)=CC=2)[N+]([O-])=O)CCC1(OC)CC1=CC=CC=C1C1=CC=CC=C1 FESBUAOKUZDLTH-UHFFFAOYSA-N 0.000 description 1
- URHQLJZDQJSUAP-UHFFFAOYSA-N n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)=CC=C1NCC1CCCCC1 URHQLJZDQJSUAP-UHFFFAOYSA-N 0.000 description 1
- HIRNJNRQLZDFNJ-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-(2-morpholin-4-ylethoxy)-4-[(2-phenylphenyl)methyl]piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCOCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 HIRNJNRQLZDFNJ-UHFFFAOYSA-N 0.000 description 1
- YQZFFORYDMFRFX-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-piperidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 YQZFFORYDMFRFX-UHFFFAOYSA-N 0.000 description 1
- ZAWJTLHOGGQBHK-UHFFFAOYSA-N n-[4-[(2-methyl-1-phenylsulfanylpropan-2-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]-4-(2-pyrrolidin-1-ylethoxy)piperidin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCC(CC=3C(=CC=CC=3)C=3C=CC=CC=3)(CC2)OCCN2CCCC2)C=C([N+]([O-])=O)C=1NC(C)(C)CSC1=CC=CC=C1 ZAWJTLHOGGQBHK-UHFFFAOYSA-N 0.000 description 1
- GWWKHWVMGIDRJV-UHFFFAOYSA-N n-[4-[2-(benzenesulfonyl)ethylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCS(=O)(=O)C1=CC=CC=C1 GWWKHWVMGIDRJV-UHFFFAOYSA-N 0.000 description 1
- QFTHNWMZIFAVIM-UUWRZZSWSA-N n-[4-[[(2r)-1-(benzenesulfonyl)-4-(dimethylamino)-4-oxobutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CC(=O)N(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)S(=O)(=O)C1=CC=CC=C1 QFTHNWMZIFAVIM-UUWRZZSWSA-N 0.000 description 1
- MWQLXEGHOOUBPU-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 MWQLXEGHOOUBPU-PGUFJCEWSA-N 0.000 description 1
- MZFYCZAOGZJWFS-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methoxyphenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 MZFYCZAOGZJWFS-PGUFJCEWSA-N 0.000 description 1
- SXVPYUDADYMHAM-PGUFJCEWSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-methylsulfanylphenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C1=CC(SC)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=CC(=CC=2)C(=O)NS(=O)(=O)C=2C=C(C(N[C@H](CCN(C)C)CSC=3C=CC=CC=3)=CC=2)[N+]([O-])=O)CC1 SXVPYUDADYMHAM-PGUFJCEWSA-N 0.000 description 1
- WFNXNJFAMBCPBZ-VQJSHJPSSA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-phenylphenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WFNXNJFAMBCPBZ-VQJSHJPSSA-N 0.000 description 1
- JNLJZWQYNKWQNQ-PGUFJCEWSA-N n-[4-[[(2r)-4-(tert-butylamino)-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CC(=O)NC(C)(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 JNLJZWQYNKWQNQ-PGUFJCEWSA-N 0.000 description 1
- WWXOJYSTEJWJKZ-PSXMRANNSA-N n-[4-[[(2r)-4-[tert-butyl(methyl)amino]-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CC(=O)N(C)C(C)(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 WWXOJYSTEJWJKZ-PSXMRANNSA-N 0.000 description 1
- RCWKMXDOHJPYSM-JGCGQSQUSA-N n-[4-[[(2r)-4-amino-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C([C@@H](CC(=O)N)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 RCWKMXDOHJPYSM-JGCGQSQUSA-N 0.000 description 1
- DFEGKCOCDVJOAB-QLKFWGTOSA-N n-[4-[[(2s)-4-(dimethylamino)-2-methyl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@](C)(CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DFEGKCOCDVJOAB-QLKFWGTOSA-N 0.000 description 1
- KOVWUSMJBCNXMH-QNGWXLTQSA-N n-[4-[[(2s)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C([C@H](NC1=CC=C(C=C1[N+](=O)[O-])S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC=CC=2)CC1)CSC=1C=CC=CC=1)CN1CCOCC1 KOVWUSMJBCNXMH-QNGWXLTQSA-N 0.000 description 1
- YAHSMMRTGVSUCR-UHFFFAOYSA-N n-[4-[[1,2-diphenylethyl(methyl)carbamoyl]-methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)CC1=CC=CC=C1 YAHSMMRTGVSUCR-UHFFFAOYSA-N 0.000 description 1
- XTYOWTJIZSXBAW-UHFFFAOYSA-N n-[4-[[4-(benzenesulfonyl)oxolan-3-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NC1COCC1S(=O)(=O)C1=CC=CC=C1 XTYOWTJIZSXBAW-UHFFFAOYSA-N 0.000 description 1
- ZQRGSIDCMVQMSM-UHFFFAOYSA-N n-[4-[[[2-(dimethylamino)-1-phenylethyl]-methylcarbamoyl]-methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C(CN(C)C)N(C)C(=O)N(C)C(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=CC=C1 ZQRGSIDCMVQMSM-UHFFFAOYSA-N 0.000 description 1
- UXAQLSDITLOXLS-UHFFFAOYSA-N n-[4-[[benzhydryl(methyl)carbamoyl]-methylamino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 UXAQLSDITLOXLS-UHFFFAOYSA-N 0.000 description 1
- KBKPKMBLGUXTEM-UHFFFAOYSA-N n-[4-[methyl-[methyl-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]carbamoyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C([N+]([O-])=O)C=1N(C)C(=O)N(C)C(C=1C=CC=CC=1)CN1CCN(C)CC1 KBKPKMBLGUXTEM-UHFFFAOYSA-N 0.000 description 1
- QULHVPMNZBNJDM-UHFFFAOYSA-N n-[4-[methyl-[methyl-[4-(trifluoromethoxy)phenyl]carbamoyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1N(C)C(=O)N(C)C(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C=C1)=CC=C1N(CC1)CCN1CC1=CC=CC=C1C1=CC=CC=C1 QULHVPMNZBNJDM-UHFFFAOYSA-N 0.000 description 1
- HERAGAPOTSDDHD-UHFFFAOYSA-N n-[6-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-1h-indazol-3-yl]-3-nitro-4-(2-phenylsulfanylethylamino)benzenesulfonamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC=2C3=CC=C(C=C3NN=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)=CC=C1NCCSC1=CC=CC=C1 HERAGAPOTSDDHD-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- HLEKYJVHEBHTMR-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O.CCCCC(N)=O HLEKYJVHEBHTMR-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229950004608 talampanel Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- FYKMEFWPQVGWMO-UHFFFAOYSA-N tert-butyl 4-[2-nitro-4-[[4-[4-[(2-phenylphenyl)methyl]piperazin-1-yl]benzoyl]sulfamoyl]phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(S(=O)(=O)NC(=O)C=2C=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC=CC=3)CC2)C=C1[N+]([O-])=O FYKMEFWPQVGWMO-UHFFFAOYSA-N 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229950010980 tiplimotide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003107 tramadol hydrochloride Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960004664 xaliproden Drugs 0.000 description 1
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98847907P | 2007-11-16 | 2007-11-16 | |
| US60/988,479 | 2007-11-16 | ||
| PCT/US2008/083478 WO2009064938A1 (en) | 2007-11-16 | 2008-11-14 | Method of treating arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008322595A1 AU2008322595A1 (en) | 2009-05-22 |
| AU2008322595B2 true AU2008322595B2 (en) | 2014-01-30 |
Family
ID=40291332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008322595A Ceased AU2008322595B2 (en) | 2007-11-16 | 2008-11-14 | Method of treating arthritis |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20090176785A1 (enExample) |
| EP (1) | EP2231159A1 (enExample) |
| JP (2) | JP5450434B2 (enExample) |
| KR (1) | KR101585848B1 (enExample) |
| CN (1) | CN101969951B (enExample) |
| AU (1) | AU2008322595B2 (enExample) |
| CA (1) | CA2705294C (enExample) |
| DO (1) | DOP2013000169A (enExample) |
| IL (2) | IL205501A (enExample) |
| MX (1) | MX2010005395A (enExample) |
| NZ (2) | NZ601350A (enExample) |
| RU (2) | RU2526201C2 (enExample) |
| WO (1) | WO2009064938A1 (enExample) |
| ZA (1) | ZA201003434B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| DK2550258T3 (en) | 2010-03-25 | 2015-12-07 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PH12013501006A1 (en) | 2010-11-23 | 2022-03-30 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2948287T3 (es) | 2017-08-23 | 2023-09-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| PH12022551091A1 (en) | 2019-11-05 | 2024-06-24 | Abbvie Deutschland | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| AU2021228622A1 (en) | 2020-02-24 | 2022-10-13 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Hot melt extruded solid dispersions containing a BCL2 inhibitor |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965745A (en) * | 1995-10-10 | 1999-10-12 | Pfizer Inc | Indole carbamates as leukotriene antagonists |
| WO2005012296A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| WO2006011005A1 (en) * | 2004-07-16 | 2006-02-02 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| CN1425004A (zh) * | 2000-03-21 | 2003-06-18 | 宝洁公司 | 含杂环侧链的n－取代的金属蛋白酶抑制剂 |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| TWI337608B (en) * | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
-
2008
- 2008-11-14 KR KR1020107013163A patent/KR101585848B1/ko not_active Expired - Fee Related
- 2008-11-14 JP JP2010534194A patent/JP5450434B2/ja not_active Expired - Fee Related
- 2008-11-14 RU RU2012143212/15A patent/RU2526201C2/ru not_active IP Right Cessation
- 2008-11-14 AU AU2008322595A patent/AU2008322595B2/en not_active Ceased
- 2008-11-14 WO PCT/US2008/083478 patent/WO2009064938A1/en not_active Ceased
- 2008-11-14 US US12/270,987 patent/US20090176785A1/en not_active Abandoned
- 2008-11-14 NZ NZ601350A patent/NZ601350A/xx not_active IP Right Cessation
- 2008-11-14 CA CA2705294A patent/CA2705294C/en not_active Expired - Fee Related
- 2008-11-14 EP EP08850262A patent/EP2231159A1/en not_active Withdrawn
- 2008-11-14 MX MX2010005395A patent/MX2010005395A/es active IP Right Grant
- 2008-11-14 CN CN2008801242231A patent/CN101969951B/zh not_active Expired - Fee Related
- 2008-11-14 RU RU2010123796/15A patent/RU2472509C2/ru not_active IP Right Cessation
- 2008-11-14 NZ NZ585085A patent/NZ585085A/xx not_active IP Right Cessation
-
2010
- 2010-05-02 IL IL205501A patent/IL205501A/en not_active IP Right Cessation
- 2010-05-14 ZA ZA2010/03434A patent/ZA201003434B/en unknown
-
2013
- 2013-07-23 DO DO2013000169A patent/DOP2013000169A/es unknown
- 2013-07-24 IL IL227641A patent/IL227641A0/en unknown
- 2013-11-11 JP JP2013232754A patent/JP5667684B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,429 patent/US20160101109A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965745A (en) * | 1995-10-10 | 1999-10-12 | Pfizer Inc | Indole carbamates as leukotriene antagonists |
| WO2005012296A1 (en) * | 2003-07-28 | 2005-02-10 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| WO2006011005A1 (en) * | 2004-07-16 | 2006-02-02 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| IL205501A0 (en) | 2010-12-30 |
| KR101585848B1 (ko) | 2016-01-15 |
| NZ585085A (en) | 2012-08-31 |
| MX2010005395A (es) | 2010-06-02 |
| CN101969951A (zh) | 2011-02-09 |
| CN101969951B (zh) | 2012-10-31 |
| JP2014065716A (ja) | 2014-04-17 |
| US20090176785A1 (en) | 2009-07-09 |
| NZ601350A (en) | 2013-08-30 |
| WO2009064938A1 (en) | 2009-05-22 |
| KR20100099172A (ko) | 2010-09-10 |
| RU2472509C2 (ru) | 2013-01-20 |
| ZA201003434B (en) | 2011-10-26 |
| JP2011503199A (ja) | 2011-01-27 |
| WO2009064938A9 (en) | 2009-08-06 |
| RU2010123796A (ru) | 2011-12-27 |
| CA2705294C (en) | 2016-05-17 |
| JP5450434B2 (ja) | 2014-03-26 |
| CA2705294A1 (en) | 2009-05-22 |
| RU2526201C2 (ru) | 2014-08-20 |
| EP2231159A1 (en) | 2010-09-29 |
| US20160101109A1 (en) | 2016-04-14 |
| IL205501A (en) | 2013-08-29 |
| AU2008322595A1 (en) | 2009-05-22 |
| RU2012143212A (ru) | 2014-04-20 |
| JP5667684B2 (ja) | 2015-02-12 |
| IL227641A0 (en) | 2013-09-30 |
| DOP2013000169A (es) | 2013-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008322595B2 (en) | Method of treating arthritis | |
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| AU2023229524B2 (en) | Combination therapy of tetracyclic quinolone analogs for treating cancer | |
| US12486290B2 (en) | Isoindolinone and indazole compounds for the degradation of EGFR | |
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| RU2005135958A (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена | |
| IL175609A (en) | N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed | |
| WO2019040706A1 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| RU2017116598A (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| WO2012127506A4 (en) | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | |
| CN1523991A (zh) | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 | |
| JP2005538099A5 (enExample) | ||
| JP2018526391A5 (enExample) | ||
| KR20140027939A (ko) | 지양제 | |
| CN101557806A (zh) | 使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物 | |
| US20230405015A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| AU2013329865B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor | |
| WO2020078788A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| JP2024535799A (ja) | Ｂｔｋ阻害剤及びｐｉ３キナーゼ阻害剤の組み合わせを使用したがん治療の方法 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| RU2007111704A (ru) | 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения | |
| RU2007131105A (ru) | Производные пиразола, предназначенные для ингибирования циклинзависимых киназ (cdk) и киназ гликогенсинтазы (gsk) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ABBVIE INC. Free format text: FORMER APPLICANT(S): ABBOTT LABORATORIES |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |